BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31074165)

  • 1. Implication of myeloid differentiation factor 88 inhibitor TJ-M2010-5 for therapeutic intervention of hepatocellular carcinoma.
    Liu J; Zhang X; Wang H; Zhang M; Peng Y; Li M; Xie L; Jiang F; Gong Y; Zhao Q; Zhou P
    Hepatol Res; 2019 Oct; 49(10):1182-1194. PubMed ID: 31074165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer.
    Xie L; Jiang FC; Zhang LM; He WT; Liu JH; Li MQ; Zhang X; Xing S; Guo H; Zhou P
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26712311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term use of MyD88 inhibitor TJ-M2010-5 prevents d-galactosamine/lipopolysaccharide-induced acute liver injury in mice.
    Ding Z; Du D; Yang Y; Yang M; Miao Y; Zou Z; Zhang X; Li Z; Zhang X; Zhang L; Wang X; Zhao Y; Jiang J; Jiang F; Zhou P
    Int Immunopharmacol; 2019 Feb; 67():356-365. PubMed ID: 30583234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MyD88 inhibitor TJ-M2010-2 suppresses proliferation, migration and invasion of breast cancer cells by regulating MyD88/GSK-3β and MyD88/NF-κB signalling pathways.
    Liu JH; Chen C; Li ZY; Zou ZM; Gao DC; Zhang X; Kuang XW; Sun ZH; Zheng WJ; Zhou P; Sun SR
    Exp Cell Res; 2020 Sep; 394(2):112157. PubMed ID: 32610185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond knockout: A novel homodimerization-targeting MyD88 inhibitor prevents and cures type 1 diabetes in NOD mice.
    Zhang X; Xing S; Li M; Zhang L; Xie L; He W; Liu J; Chang S; Jiang F; Zhou P
    Metabolism; 2016 Sep; 65(9):1267-77. PubMed ID: 27506734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TJ-M2010-5, a novel CNS drug candidate, attenuates acute cerebral ischemia-reperfusion injury through the MyD88/NF-κB and ERK pathway.
    Li Z; Zhao M; Zhang X; Lu Y; Yang Y; Xie Y; Zou Z; Zhou L; Shang R; Zhang L; Jiang F; Du D; Zhou P
    Front Pharmacol; 2022; 13():1080438. PubMed ID: 36588708
    [No Abstract]   [Full Text] [Related]  

  • 7. TJ-M2010-5, A self-developed MyD88 inhibitor, attenuates liver fibrosis by inhibiting the NF-κB pathway.
    Xie Y; Du D; Zhang L; Yang Y; Zou Z; Li Z; Zhou L; Shang R; Zhou P
    Chem Biol Interact; 2022 Feb; 354():109839. PubMed ID: 35101388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating the conformation of the TIR domain by a neoteric MyD88 inhibitor leads to the separation of GVHD from GVT.
    Xing S; Zhang X; Huang X; Xie L; Jiang F; Zhou P
    Leuk Lymphoma; 2019 Jun; 60(6):1528-1539. PubMed ID: 30501537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of MyD88 by a novel inhibitor reverses two-thirds of the infarct area in myocardial ischemia and reperfusion injury.
    Miao Y; Ding Z; Zou Z; Yang Y; Yang M; Zhang X; Li Z; Zhou L; Zhang L; Zhang X; Du D; Jiang F; Zhou P
    Am J Transl Res; 2020; 12(9):5151-5169. PubMed ID: 33042411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of a MyD88 inhibitor alleviates rejection and inflammation in xenotransplantation by inhibiting dendritic cells activation and trained immunity in macrophages.
    Li Z; Zhao M; Yang Y; Zou Z; Zhang L; Jiang F; Du D; Zhou P
    Int Immunopharmacol; 2024 Mar; 130():111664. PubMed ID: 38377850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TJ-M2010-5, a novel MyD88 inhibitor, corrects R848-induced lupus-like immune disorders of B cells in vitro.
    Zou Z; Du D; Miao Y; Yang Y; Xie Y; Li Z; Zhou L; Zhang L; Zhou P; Jiang F
    Int Immunopharmacol; 2020 Aug; 85():106648. PubMed ID: 32504998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.
    Li C; Zhang LM; Zhang X; Huang X; Liu Y; Li MQ; Xing S; Yang T; Xie L; Jiang FC; Jiang HY; He WT; Zhou P
    Transplantation; 2017 Feb; 101(2):284-293. PubMed ID: 27607533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of MyD88 homodimerization counteracts renal ischemia reperfusion-induced progressive renal injury in vivo and in vitro.
    Zhang LM; Liu JH; Xue CB; Li MQ; Xing S; Zhang X; He WT; Jiang FC; Lu X; Zhou P
    Sci Rep; 2016 Jun; 6():26954. PubMed ID: 27246399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Inhibitor of Homodimerization Targeting MyD88 Ameliorates Renal Interstitial Fibrosis by Counteracting TGF-β1-Induced EMT in Vivo and in Vitro.
    Liu JH; He L; Zou ZM; Ding ZC; Zhang X; Wang H; Zhou P; Xie L; Xing S; Yi CZ
    Kidney Blood Press Res; 2018; 43(5):1677-1687. PubMed ID: 30380557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells play an essential role in transplantation responses via myeloid differentiation factor 88 signaling.
    Li C; Huang X; Liu Y; Yang T; Zhang L; Li M; Jiang F; Huang W; Zhou P
    Transplant Proc; 2013 Jun; 45(5):1842-5. PubMed ID: 23731896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TJ-M2010-5 Attenuates Severe Myocardial Ischemia/Reperfusion Injury in Heart Transplantation by Inhibiting MyD88 Homodimerization In Vivo.
    Yang H; Zhou P; Li Q; Zhou X; Li J; Wang J; Wang J; Zhao Y; Yang B; Zhang B; Dai C; Zou Z; Yang Y; Chen Z
    J Cardiovasc Transl Res; 2022 Dec; 15(6):1366-1376. PubMed ID: 35411418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypothermic oxygenated perfusion combined with TJ-M2010-5 alleviates hepatic ischemia-reperfusion injury in donation after circulatory death.
    Zhou W; Peng S; Du P; Zhou P; Xue C; Ye Q
    Int Immunopharmacol; 2022 Apr; 105():108541. PubMed ID: 35063749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDSC suppresses T cell antitumor immunity in CAC via GPNMB in a MyD88-dependent manner.
    Wang B; Wang L; Shang R; Xie L
    Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38140790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
    Cai X; Hu X; Cai B; Wang Q; Li Y; Tan X; Hu H; Chen X; Huang J; Cheng J; Jing X
    Oncol Rep; 2013 Nov; 30(5):2449-57. PubMed ID: 24008375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel MyD88 inhibitor attenuates allograft rejection after heterotopic tracheal transplantation in mice.
    Yang M; Chen G; Zhang X; Ding Z; Miao Y; Yang Y; Chen ZK; Jiang F; Chang S; Zhou P
    Transpl Immunol; 2019 Apr; 53():1-6. PubMed ID: 30472390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.